News | September 13, 2021
Boehringer Ingelheim and Twist Bioscience ink antibody discovery collaboration
Research collaboration covers multiple antibody research programs
Research collaboration covers multiple antibody research programs
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Subscribe To Our Newsletter & Stay Updated
